SHELTON, Conn., Feb. 1, 2016 /PRNewswire/ -- NanoViricides,
Inc. (NYSE MKT: NNVC (the "Company") announced today that it has
entered into an agreement with the University
of Wisconsin for the evaluation of its nanoviricides® drug
candidates in models of ocular herpes virus infections.
The studies will be performed in the laboratory of Dr.
Curtis Brandt, an expert in herpes
simplex virus infections and in evaluating anti-viral agents. The
Company has previously reported the successes of its nanoviricides
drug candidates in pre-clinical studies of dermal herpes virus
infections in mouse models. The studies in Dr. Brandt's
laboratory will be critical in optimizing its anti-herpes drug
candidates against ocular herpes virus infections. The goal of
these studies will be to identify a drug development candidate as a
treatment for ocular keratitis in humans caused by herpes simplex
virus infections.
Dr. Brandt is Professor in the Departments of Ophthalmology and
Visual Sciences, Medical Microbiology and Immunology, and Director
of the Vision Research Core at the University of Wisconsin.
The studies will be conducted by Collaborative Ophthalmic Research
Laboratories, CORL, at the University.
"We are progressing rapidly in developing drug candidates
against different herpesvirus infections and related indications,"
said Dr. Eugene Seymour, MD, MPH,
CEO of the Company, "Dr. Brandt's expertise and this agreement with
CORL at the University of Wisconsin
will help us identify a clinical drug candidate against herpes
keratitis (HK) in a relatively short time frame."
About CORL:
CORL is a collaborative team of internationally recognized
vision scientists founded on providing world-class vision research
support for industry at the University of Wisconsin. CORL
understands industry's timeline-driven culture and can collaborate
with industry via fee-for-service agreements.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development
stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo - http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-signs-agreement-with-the-university-of-wisconsin-for-testing-of-anti-viral-candidates-300212613.html
SOURCE NanoViricides, Inc.